Compare McKesson Corporation (MCK) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs YieldMax MSTR Option Income Strategy ETF — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while YieldMax MSTR Option Income Strategy ETF trades at $13.44. The key difference: McKesson Corporation pays a 0.39% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and McKesson Corporation is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MCK | MSTY | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $108.80 |
52-Week Low | $659.01 | $11.55 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
MSTY trades at $13.12, up 2.34% today, but remains in a bearish technical trend with significant price depreciation year-to-date. The ETF generates high weekly dividend distributions, but these are offset by substantial capital erosion, as highlighted by financial media. Key technical indicators signal selling pressure, with moving averages and oscillators predominantly bearish or neutral.
The outlook is cautious due to structural risks in the covered-call strategy capping upside potential while exposing investors to full downside. High distributions may not be sustainable if funded by return of capital. Investor sentiment is negative, with media reports emphasizing total return losses outweighing dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
